CARB-X FUNDS FACILE THERAPEUTICS TO DEVELOP A NEW TREATMENT TO PREVENT RECURRING C. DIFFICILE BACTERIAL INFECTIONS
CARB-X is awarding Facile Therapeutics, based in Belmont, California, USA, up to $1.26 million to develop a new orally bioavailable drug to treat recurring infections caused by Clostridium difficile. Facile could receive up to $17 million more in additional funding from CARB-X if the project achieves certain development milestones, for a potential total of $18.26 million.
“C. difficile represents an urgent global health threat and CARB-X is funding and supporting innovative R&D projects, like Facile’s Ebselen project, to address this growing threat,” said Erin Duffy, Chief of Research and Development of CARB-X, a non-profit partnership based at Boston University School of Law, dedicated to supporting early development antibacterial research around the world. “This is a terrific example of an attempt to repurpose a compound for use in the infectious-disease arena. If successful and ultimately approved for use in patients, Facile’s project could represent tremendous progress in the prevention of recurrent C. difficile infections, and save many lives.”
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!